Evolving Critical Care Needs and Outcomes in Andes Virus-Associated Hantavirus Cardiopulmonary Syndrome: Insights from a National Chilean Cohort
Posted inCritical Care Infectious Diseases news

Evolving Critical Care Needs and Outcomes in Andes Virus-Associated Hantavirus Cardiopulmonary Syndrome: Insights from a National Chilean Cohort

This study evaluates respiratory support and mortality trends in Andes virus-induced hantavirus cardiopulmonary syndrome (HCPS) across Chile, highlighting increased mortality during the COVID-19 pandemic period and a high requirement for invasive respiratory interventions.
Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis
Posted inHematology-Oncology news

Optimizing Bridging Therapy Before BCMA-Directed CAR T-Cell Treatment in Relapsed/Refractory Multiple Myeloma: A Real-World Multicenter Analysis

Bridging therapy before BCMA-directed CAR T-cell infusion in relapsed/refractory multiple myeloma impacts disease control and outcomes. This study analyzes regimen efficacy and safety in 399 patients, highlighting variable responses and safety profiles tied to disease burden and biological risk.
High Pesticide Exposure Events and Olfactory Dysfunction: Integrating Subjective and Objective Evidence from Agricultural Cohorts
Posted inClinical Updates news Otorhinolaryngology Public Health

High Pesticide Exposure Events and Olfactory Dysfunction: Integrating Subjective and Objective Evidence from Agricultural Cohorts

Emerging evidence links high pesticide exposure events (HPEEs) in farmers to increased self-reported olfactory dysfunction, though objective smell testing yields inconclusive associations, highlighting critical gaps and methodological considerations in assessing pesticide-related olfactory impairment.
Teplizumab Preserves Beta Cell Function in Youth with Newly Diagnosed Type 1 Diabetes: Insights from the PROTECT Trial Per-Protocol Analysis
Posted inDiabetes & Endocrinology news Pediatrics

Teplizumab Preserves Beta Cell Function in Youth with Newly Diagnosed Type 1 Diabetes: Insights from the PROTECT Trial Per-Protocol Analysis

The PROTECT trial's per-protocol analysis confirms teplizumab's efficacy in preserving beta cell function, reducing insulin needs, and improving glycemic control in children and adolescents newly diagnosed with stage 3 type 1 diabetes, regardless of HLA subtype or autoantibody profile.